UTILITY PATENT APPLICATION **TRANSMITTAL**

+

Under the Paperwork Reduction	Act of 1995, no persons	s are required to respo	and to a collection of information unless it displays a valid OMB control number		
ITY PLICATION MITTAL	Attorney Docket No.		MRIN-010		
	First Inventor		BYRD, EDWARD A.		
	Title	ORAL FORMULATION OF LIPID SOLUBLE THIAMINE AND LIPOIC ACID			

(Only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

Express Mail Label No. EV 334 000 263 US Commissioner for Patents ADDRESS TO: Mail Stop Patent Application

SEE MPEP chapter 600 concerning utility patent application contents.			P.O. Box 1450 Alexandria, VA 22313-1450					
1. Fe	ee Transmittal ubmit an original and s	Form (e.g., PTO/SB/17) a duplicate for fee processing) 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)						PT0
	Applicant claims small entity status. See 37 CFR 1.27.			8. Nucleotide and/or Amino Acid Sequence Submission fif applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on:				
	Specification [Total Pages: 56] (preferred arrangement set forth below)				40 =			
-Descriptive title of the invention -Cross Reference to Related Applications -Statement Regarding Fed sponsored R & D -Reference to sequence listing, a table, or a computer program listing appendix -Background of the Invention -Brief Summary of the Invention				i ☐ CD-ROM or CD-R (2 copies); or ii ☐ paper c. ☐ Statements verifying identity of above copies				
				ACCOMPANYING APPLICATION PARTS				
-Brief Description of the Drawings (if filed) -Detailed Description -Claim(s) -Abstract of the Disclosure 4. Drawing(s) (35 U.S.C. 113) [Total Pages: 1] 5. Oath or Declaration [Total Pages:] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) Named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b) 6. Application Data Sheet. See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and supply or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (
For CONTIN Box 5b, is co	onsidered a p	DIVISIONAL APPS on art of the disclosure	ly: The entire dis of the accompan	ying continuati	prior application, from vion or divisional applicational omitted from the suited from the suit	tion and is herel	y incorporated by	
-					ENCE ADDRESS			
Customer Number or Bar Code Label			or Correspondence address below					
Name	(Insert Customer No. or Attach			par code label nere)	,			
200 Middlefield Road, Suite 200								
Address		Τ~ Τ		- · · ·	1 1	104005		
City		Menlo Park Star		State	California	Zip Code	94025	
Country	Country United States of		America	Telephone	(650) 327-3400	Fax	(650) 327-3231	
					Registration No. (Attorne		28,807	
Signature	<u> </u>	<u> </u>	lica			Date	October 23, 200	3

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 3 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.